DUBLIN--(BUSINESS WIRE)--Jun 5, 2018--The "Macular Edema - Pipeline Review, H1 2018" report has been added to ResearchAndMarkets.com's offering.

Macular Edema - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Macular Edema (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.

The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Macular Edema (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Macular Edema and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase II, Preclinical and Discovery stages are 2, 7 and 1 respectively.

Companies Mentioned

ActiveSite Pharmaceuticals Inc Coherus BioSciences Inc EyeGate Pharmaceuticals Inc Lupin Ltd Mabion SA OMEICOS Therapeutics GmbH Promedior Inc Taiwan Liposome Company Ltd Xbrane Biopharma AB

Key Topics Covered

Introduction Report Coverage Macular Edema - Overview Macular Edema - Therapeutics Development Pipeline Overview Pipeline by Companies Products under Development by Companies Macular Edema - Therapeutics Assessment Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Macular Edema - Companies Involved in Therapeutics Development ActiveSite Pharmaceuticals Inc Coherus BioSciences Inc EyeGate Pharmaceuticals Inc Lupin Ltd Mabion SA OMEICOS Therapeutics GmbH Promedior Inc Taiwan Liposome Company Ltd Xbrane Biopharma AB Macular Edema - Drug Profiles ACX-107 - Drug Profile Product Description Mechanism Of Action R&D Progress aflibercept biosimilar - Drug Profile Product Description Mechanism Of Action R&D Progress ASPPDC-020 - Drug Profile Product Description Mechanism Of Action R&D Progress dexamethasone phosphate - Drug Profile Product Description Mechanism Of Action R&D Progress dexamethasone sodium phosphate SR 1 - Drug Profile Product Description Mechanism Of Action R&D Progress OMT-28 - Drug Profile Product Description Mechanism Of Action R&D Progress PRM-167 - Drug Profile Product Description Mechanism Of Action R&D Progress ranibizumab biosimilar - Drug Profile Product Description Mechanism Of Action R&D Progress ranibizumab biosimilar - Drug Profile Product Description Mechanism Of Action R&D Progress ranibizumab biosimilar - Drug Profile Product Description Mechanism Of Action R&D Progress Macular Edema - Dormant Projects Macular Edema - Discontinued Products Macular Edema - Product Development Milestones Featured News & Press Releases

For more information about this report visit https://www.researchandmarkets.com/research/dzgljn/macular_edema?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180605006419/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Cardiovascular Drugs ,Optical Disorders Drugs

KEYWORD:

INDUSTRY KEYWORD: HEALTH CARDIOLOGY PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 06/05/2018 12:56 PM/DISC: 06/05/2018 12:56 PM

http://www.businesswire.com/news/home/20180605006419/en